Mostrando 7 resultados de: 7
Publisher
European Journal of Clinical Pharmacology(2)
Therapeutic Drug Monitoring(2)
British Journal of Clinical Pharmacology(1)
OMICS A Journal of Integrative Biology(1)
Psychopharmacology series(1)
Área temáticas
Farmacología y terapéutica(6)
Enfermedades(2)
Medicina y salud(2)
Bioquímica(1)
Ciencias sociales(1)
Objetivos de Desarrollo Sostenible
ODS 3: Salud y bienestar(7)
ODS 17: Alianzas para lograr los objetivos(3)
ODS 12: Producción y consumo responsables(2)
ODS 9: Industria, innovación e infraestructura(2)
Origen
scopus(7)
CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers
ArticleAbstract: Objective: This study analyzed the frequency of CYP2C9 variant alleles and evaluated the impact of CPalabras claves:CYP2C9, Diclofenac, GenotypingAutores:Adrián LLerena, Berecz R., Dahl M.L., Dorado P., Norberto M., Yasar U.Fuentes:scopusAn Appeal to the Global Health Community for a Tripartite Innovation: An "essential Diagnostics List," "health in All Policies," and "see-Through 21<sup>st</sup> Century Science and Ethics"
ReviewAbstract: Diagnostics spanning a wide range of new biotechnologies, including proteomics, metabolomics, and naPalabras claves:Autores:Adrián LLerena, Barlas Ö., Birch K., Boehme C., Borda-Rodriguez A., Byne W.M., Chaverneff F., Coşkun Y., Dahl M.L., Dereli T., Diwakar S., Dove E.S., Elbeyli L., Endrenyi L., Eroʇlu-Kesim B., Ferguson L.R., Güngör K., Gürsoy U.K., Hekim N., Huzair F., Kaushik K., Kickbusch I., Klroʇlu O., Kolker E., Könönen E., Lin B., Malhan F., Nair B., Özdemir V., Patrinos G.P., Sardaş S., Sert Ö., Srivastava S., Steuten L.M.G., Toraman C., Vayena E., Wang W., Warnich L.Fuentes:scopusDisposition of clozapine in man: lack of association with debrisoquine and S‐mephenytoin hydroxylation polymorphisms.
ArticleAbstract: A large interindividual variability has previously been demonstrated in the bioavailability, steady‐Palabras claves:Autores:Adrián LLerena, Bertilsson L., Bondesson U., Dahl M.L., Lindstrom L.Fuentes:scopusDisposition of the neuroleptics perphenazine, zuclopenthixol, and haloperidol cosegregates with polymorphic debrisoquine hydroxylation.
ReviewAbstract:Palabras claves:Autores:Adrián LLerena, Bertilsson L., Dahl M.L., Ekqvist B.Fuentes:scopusHaloperidol disposition is dependent on debrisoquine hydroxylation phenotype
ArticleAbstract: To investigate the importance of genetic factors for the regulation of haloperidol metabolism, we stPalabras claves:debrisoquine, Haloperidol, humans, pharmacogeneticsAutores:Adrián LLerena, Alm C., Bertilsson L., Dahl M.L., Ekqvist B.Fuentes:scopusHaloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: Increased plasma levels of the reduced metabolite in poor metabolizers
ArticleAbstract: We have previously shown that the disposition of haloperidol is decreased in poor (PM) compared to ePalabras claves:debrisoquine, humans, pharmacogenetics, Reduced haloperidolAutores:Adrián LLerena, Bertilsson L., Dahl M.L., Ekqvist B.Fuentes:scopusThioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype
ArticleAbstract: Background: Approximately 7% of Caucasians have genetically impaired activity of the cytochrome P450Palabras claves:Cytochrome p450, pharmacogenetics, smoking, ThioridazineAutores:Adrián LLerena, Berecz R., Dahl M.L., De la Rubia A., Dorado P., Fernández-Salguero P.Fuentes:scopus